These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1276611)

  • 21. Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.
    Cuschieri A
    Br J Surg; 1973 Oct; 60(10):800-3. PubMed ID: 4748385
    [No Abstract]   [Full Text] [Related]  

  • 22. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract]   [Full Text] [Related]  

  • 23. Urinary hydroxyproline in the management of breast cancer.
    Cuschieri A
    World J Surg; 1977 May; 1(3):299-302. PubMed ID: 883324
    [No Abstract]   [Full Text] [Related]  

  • 24. Circadian rhythm of total urinary hydroxyproline excretion and 3-H hydroxyproline test.
    Radom S; Zulawski M; Dahlig E
    Clin Chim Acta; 1972 Jun; 39(1):277-8. PubMed ID: 4556834
    [No Abstract]   [Full Text] [Related]  

  • 25. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE; Pachas WN; Pinals RS; Krant MJ
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract]   [Full Text] [Related]  

  • 26. The significance of hydroxyprolinuia for the proof of bone metastases of tumours.
    Mirejovská E; Beska F; Pitronová M
    Neoplasma; 1968; 15(4):433-8. PubMed ID: 5684467
    [No Abstract]   [Full Text] [Related]  

  • 27. [17-Hydroxycorticoid excretion in breast carcinoma].
    Heise E; Görlich M
    Arch Geschwulstforsch; 1973; 41(1):43-51. PubMed ID: 4700695
    [No Abstract]   [Full Text] [Related]  

  • 28. Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
    Radom S; Zulawski M; Golebiowska D
    Pol Med J; 1972; 11(4):809-14. PubMed ID: 4342776
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors influencing prognosis in carcinoma of breast.
    Chitania KM
    J Indian Med Assoc; 1973 Aug; 61(4):178-81. PubMed ID: 4774795
    [No Abstract]   [Full Text] [Related]  

  • 30. Breast cancer presenting initially with urinary incontinence: a case of bladder metastasis from breast cancer.
    Soon PS; Lynch W; Schwartz P
    Breast; 2004 Feb; 13(1):69-71. PubMed ID: 14759720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Increase of urinary elimination of hydroxyproline in osteolytic processes].
    RUBEGNI M; RAVENNI G; DEL GIOVANE L
    Boll Soc Ital Biol Sper; 1962 Sep; 38():877-8. PubMed ID: 13982943
    [No Abstract]   [Full Text] [Related]  

  • 32. Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients.
    Frenay M; Namer M; Boublil JL; Khater R; Viot M; François E; Milano G
    Bull Cancer; 1988; 75(6):533-9. PubMed ID: 3416085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
    Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study of PBI 131 urinary elimination and collection located in breast carcinoma with or without metastasis].
    Richiger de Arranz E; Adrián R; Lencioni LJ; Staffieri JJ
    Medicina (B Aires); 1965; 25(6):345-7. PubMed ID: 15154228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormonal patterns in breast cancers].
    Kiricuta I; Frenkel Z; Munteanu S
    Arch Geschwulstforsch; 1974; 44(3):260-6. PubMed ID: 4460955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of the determination of urinary hydroxyproline (OH-P) in a group of patients with various neoplasms].
    De Benedetto A; Marchei GG; Cardinale G; Michetti M; Marchei P; Reale MG
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):275. PubMed ID: 2092132
    [No Abstract]   [Full Text] [Related]  

  • 37. The value of sequential marker estimations following mastectomy for breast cancer.
    Coombes RC; Powles TJ; Ford HT; Gazet JC; Gehrke CW; Keyser JW; Mitchell PE; Patel S; Stimson WH; Abbott M; Worwood M; Neville AM
    Eur J Cancer (1965); 1980; Suppl 1():25-30. PubMed ID: 6119202
    [No Abstract]   [Full Text] [Related]  

  • 38. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary hydroxyproline excretion in patients with metastatic carcinoma of the prostate.
    Immergut M; Nordschow CD; Tammes AR; Flocks RH
    J Urol; 1966 Oct; 96(4):570-2. PubMed ID: 5925559
    [No Abstract]   [Full Text] [Related]  

  • 40. Leucocyte ascorbic acid and urinary hydroxyproline levels in patients bearing breast cancer with skeletal metastases.
    Basu TK; Raven RW; Dickerson JW; Williams DC
    Eur J Cancer (1965); 1974 Aug; 10(8):507-11. PubMed ID: 4463001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.